Compare Matson Inc (MATX) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Natera Inc. Common Stock — how do they compare? Matson Inc trades at $237.82 (market cap $7.03B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 8.1× Matson Inc's market cap, and Matson Inc pays a 0.65% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Matson Inc for 25 Days and Natera Inc. Common Stock for 0 Days on average.
| MATX | NTRA | |
|---|---|---|
Market Cap | $7.03B | $57.03B |
Volume | 327,630 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $238.60 | $425.64 |
52-Week Low | $93.22 | $179.42 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $7.63B | $56.18B |
Dividend Yield | 0.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $235.22, up 3.31% with strong bullish momentum supported by consistent earnings beats and positive technical indicators. The stock shows robust fundamentals with a 13.41% net income margin and 17.21% ROE, while valuation metrics remain reasonable with a P/E of 15.87. Recent Q2 2026 results exceeded expectations with EPS of $4.27 versus $3.79 expected, driving positive sentiment.
Outlook remains positive with Wall Street analysts projecting 27.3% upside potential and strong institutional buying activity. Key risks include freight market volatility and competitive pressures, but the company's raised full-year guidance and dividend payments provide stability for investors seeking transportation sector exposure.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
